ROTUOC
FPRX

Regents of the University of California’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Regents of the University of California’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-22,214
Closed -$261K – 111
2014
Q3 		$261K Buy
+22,214
New +$280K 0.15% 78

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Regents of the University of California's FPRX Position: Q4 2014 in Review

Regents of the University of California sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2014, closing a stake of 22,214 shares — an estimated $261K sold.

Regents of the University of California first reported a position in FPRX in Q3 2014 and held it in 1 quarter. The position peaked at $261K in Q3 2014. 71 funds tracked by Wall St. Rank hold FPRX as of Q4 2014.

  • Regents of the University of California reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Regents of the University of California sold 22,214 Five Prime Therapeutics, Inc. shares in Q4 2014, an estimated $261K.
  • Regents of the University of California first reported a position in Five Prime Therapeutics, Inc. in Q3 2014 and held it in 1 quarter.
  • Regents of the University of California's Five Prime Therapeutics, Inc. position peaked at $261K in Q3 2014.
  • 71 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2014.

Based on Regents of the University of California's 13F filing for Q4 2014, filed 2 Feb 2015.